Status:
RECRUITING
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Type 2 Diabetes Mellitus (T2DM)
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Eligibility Criteria
Inclusion Criteria:
- Is an adult patient with a confirmed diagnosis of T2DM
- Has a body mass index (BMI) of ≥25 kg/m^2 and <39.9 kg/m^2
- Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5%
- Is on a stable dose of metformin
Exclusion Criteria:
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
Note: other protocol defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
January 15 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 28 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07465224
Start Date
January 15 2026
End Date
May 28 2027
Last Update
April 17 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
Chula Vista, California, United States, 91911